National Advertising Division Recommends BA Sports Nutrition Discontinue Its “The Rehydration Champ is Here” Claim

New York, NY – February 1, 2024 – BBB National Programs’ National Advertising Division recommended that BA Sports Nutrition, LLC (BA) discontinue the claim “The Rehydration Champ is Here” for its BodyArmor Flash I.V. Sports Drink. 

The claim at issue, which appeared on the BodyArmor Flash I.V. Sports Drink webpage and in social media advertising, was challenged by competitor Stokely-Van Camp, Inc. (SVC). BA recently introduced its Flash I.V. Sports Drink to the marketplace in the new “rapid rehydration” category.

At issue was whether BA’s “The Rehydration Champ is Here” claim conveys a comparative superiority message or is merely puffery. The National Advertising Division (NAD) concluded that one message reasonably conveyed is that Flash I.V. Sports Drink is the best on the market for rehydration, a claim that requires substantiation.

NAD noted that the quantity of electrolytes in a sports drink is not itself substantiation for a claim of superior rehydration. Although Flash I.V. has more electrolytes than Gatorlyte, in the absence of any comparative product or performance testing in the record on the rehydration benefit of Flash I.V. as compared to Gatorlyte or other competing sports drinks, NAD determined that BA’s “The Rehydration Champ is Here” claim was not supported.

Therefore, NAD recommended that BA discontinue its claim noting that nothing in its decision precludes BA from making properly supported ingredient claims for Flash I.V., or truthful and not misleading claims about the relative electrolyte content of its products and competing products.

In its advertiser statement, BA stated that it “disagrees with NAD’s conclusion but agrees to comply with the recommendation to stop using the ‘Rehydration Champ is Here’ claim, which was used specifically to advertise the launch of BODYARMOR Flash I.V. in 2023, and has already run its course.”  

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB procedures, this release shall not be used for advertising or promotional purposes.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Dr. Luke Healthcare Discontinue Treatment Claims for its Fungal Nail Renewal Product

New York, NY – July 24, 2024 – The National Advertising Division recommended Dr. Luke Healthcare discontinue certain claims for Dr. Luke’s Fungal Nail Renewal product, including health-related claims, natural claims, and claims that a doctor recommends the product or that it treats a medical condition.

Read the Decision Summary
Decision

National Advertising Division Finds Flag Image on Kendamil Infant Formula Packaging Conveys Supported Message about Products’ Origin

New York, NY – July 17, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division determined that use of a flag image on product packaging for Kendal Nutricare’s Kendamil infant formula reasonably conveys a supported message about the products’ origin. 

Read the Decision Summary
Decision

In National Advertising Division Case, GuruNanda Voluntarily Discontinues Claims Made through Influencers for Coconut Pulling Oil Products

New York, NY – July 16, 2024 – The National Advertising Division has closed a Fast-Track SWIFT challenge regarding claims that GuruNanda’s coconut pulling oil products can “naturally reverse a cavity” and “reverse cavities.” 

Read the Decision Summary
Decision

National Advertising Division Refers Health-Related Advertising Claims for Prolacta’s Human Milk Fortifier to Regulatory Agencies

New York, NY – July 15, 2024 – The National Advertising Division will refer advertising claims made by Prolacta Bioscience for its Human Milk Fortifier to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for review.

Read the Decision Summary